While selective AXL deletion in DCs, using a CD11c-eGFP-Cre line, did not result in increased anti-leukemic immunity, depletion of AXL in macrophages using Csf1r-Cre+ Axlf/f mice did increase anti-leukemic effects and prolonged survival of AML models. The gene discussed is AXL; the disease is acute myeloid leukemia.